AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19405936 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy alone
Number of subjects: 0
Study 16922703 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate daily amount of red wine
Number of subjects: 115
Study 16922703 — intervention group
Group type: COMPARATOR
Intervention: No red wine (control group)
Number of subjects: 115
Study 15130225 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil
Number of subjects: 60
Study 15130225 — intervention group
Group type: COMPARATOR
Intervention: fentanyl
Number of subjects: 60
Study 15130225 — intervention group
Group type: EXPERIMENTAL
Intervention: alfentanil
Number of subjects: 60
Study 11471853 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (10 mg/day)
Number of subjects: 479
Study 11471853 — intervention group
Group type: COMPARATOR
Intervention: Zopiclone (7.5 mg/day)
Number of subjects: 479
Study 9737456 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard thickness (STD) ePTFE grafts
Number of subjects: 108
Study 9737456 — intervention group
Group type: COMPARATOR
Intervention: Thin wall (THN) ePTFE grafts
Number of subjects: 108
Study 8291963 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen (50, 75, or 100 micrograms)
Number of subjects: 23
Study 8291963 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen (programmable pump and intrathecal catheter)
Number of subjects: 23
Study 8291963 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen (high doses > 1,000 micrograms/d)
Number of subjects: 23
Study 3174151 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine 5 mg in 5 ml of saline
Number of subjects: 20
Study 3174151 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural clonidine 150 micrograms in 5 ml of saline
Number of subjects: 20
Study 3174151 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both interventions
Number of subjects: 20
Study 31516025 — intervention group
Group type: EXPERIMENTAL
Intervention: Coencapsulated FTC/TDF
Number of subjects: 49
Study 31516025 — intervention group
Group type: EXPERIMENTAL
Intervention: Coencapsulated TFV
Number of subjects: 49
Study 31516025 — intervention group
Group type: EXPERIMENTAL
Intervention: Coencapsulated BIC/FTC/TAF
Number of subjects: 49
Study 31516025 — intervention group
Group type: COMPARATOR
Intervention: Unencapsulated formulations
Number of subjects: 49
Study 29420164 — intervention group
Group type: EXPERIMENTAL
Intervention: Apalutamide (240 mg per day)
Number of subjects: 1207
Study 29420164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1207
Study 28608540 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 82
Study 28608540 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 82
Study 25091471 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging intervention for 7 days
Number of subjects: 129
Study 22927165 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (600 mg taken four times a day for 1 week)
Number of subjects: 28
Study 22927165 — intervention group
Group type: COMPARATOR
Intervention: No ibuprofen
Number of subjects: 28
Study 21626222 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CyA) at an initial dose of 5 mg/kg for 12 months
Number of subjects: 24
Study 21626222 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone (MP) 3 pulses of 30 mg/kg followed by prednisone for 4 months
Number of subjects: 24
Study 21626222 — intervention group
Group type: COMPARATOR
Intervention: Control group (identical treatment without randomization)
Number of subjects: 24
Study 21626222 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after mean 6.1 years
Number of subjects: 24
Study 18509712 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-based RSA with contour reduction
Number of subjects: 24
Study 18509712 — intervention group
Group type: COMPARATOR
Intervention: Marker-based RSA
Number of subjects: 24
Study 16545474 — intervention group
Group type: EXPERIMENTAL
Intervention: Single fraction radiotherapy (8 Gy)
Number of subjects: 320
Study 16545474 — intervention group
Group type: COMPARATOR
Intervention: Multiple fraction radiotherapy (24 Gy in six fractions)
Number of subjects: 320
Study 11790211 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted colectomy (LAC)
Number of subjects: 449
Study 11790211 — intervention group
Group type: COMPARATOR
Intervention: Open colectomy
Number of subjects: 449
Study 10430735 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized prostaglandin (PG)I(2)
Number of subjects: 8
Study 10430735 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled NO
Number of subjects: 8
Study 10430735 — intervention group
Group type: COMPARATOR
Intervention: Intravenous PGI(2)
Number of subjects: 8
Study 10430735 — intervention group
Group type: COMPARATOR
Intervention: Systemic calcium antagonists (CAAs)
Number of subjects: 8
Study 10430735 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term therapy with aerosolized iloprost
Number of subjects: 8
Study 7582384 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispersible diclofenac (100 mg)
Number of subjects: 12
Study 7582384 — intervention group
Group type: COMPARATOR
Intervention: Enteric-coated diclofenac (100 mg)
Number of subjects: 12
Study 2262369 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated fractionation radiotherapy (72 Gy in 5 weeks, 1.6 Gy per fraction, 45 fractions)
Number of subjects: 260
Study 2262369 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy (70‐72 Gy in 7‐8 weeks, 1.8‐2.0 Gy per fraction, 35‐40 fractions)
Number of subjects: 260
Study 399090 — intervention group
Group type: EXPERIMENTAL
Intervention: Synalar cream (fluocinolone acetonide 0.025%)
Number of subjects: 0
Study 399090 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortoderm ointment (fluocinolone acetonide 0.025%)
Number of subjects: 0
Study 399090 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 6141575 — intervention group
Group type: EXPERIMENTAL
Intervention: amitriptyline
Number of subjects: 49
Study 6141575 — intervention group
Group type: EXPERIMENTAL
Intervention: alprazolam
Number of subjects: 49
Study 6141575 — intervention group
Group type: EXPERIMENTAL
Intervention: whole group
Number of subjects: 49
Study 31140297 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib 240 mg/day for 1 year after trastuzumab-based adjuvant therapy
Number of subjects: 341
Study 31140297 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 1 year after trastuzumab-based adjuvant therapy
Number of subjects: 341
Study 30305078 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated motivational interviewing and cognitive behaviour therapy (MI-CBT)
Number of subjects: 72
Study 30305078 — intervention group
Group type: COMPARATOR
Intervention: Control group (education session only)
Number of subjects: 72
Study 27292765 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.0015% PF tafluprost
Number of subjects: 190
Study 27292765 — intervention group
Group type: COMPARATOR
Intervention: 0.5% PF timolol
Number of subjects: 190
Study 24991733 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat 2 mg
Number of subjects: 21
Study 22992357 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Healthware
Number of subjects: 3786
Study 22992357 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 3786
Study 21139557 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticotherapy with mometasone furoate ointment applied once daily for 4 weeks + emollient cream applied twice a day for 4 weeks
Number of subjects: 40
Study 21139557 — intervention group
Group type: COMPARATOR
Intervention: Topical corticotherapy with mometasone furoate ointment applied once daily for 4 weeks
Number of subjects: 40
Study 17391164 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 96 mg/day
Number of subjects: 229
Study 17391164 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 192 mg/day
Number of subjects: 229
Study 17391164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study 15654072 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturally cycling women on day 12 of their menstrual cycle
Number of subjects: 48
Study 15654072 — intervention group
Group type: COMPARATOR
Intervention: Premenopausal women taking a combined monophasic oral contraceptive
Number of subjects: 48
Study 15654072 — intervention group
Group type: COMPARATOR
Intervention: Men (pseudo-cycle)
Number of subjects: 48
Study 12236025 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole stress echocardiography (n=64)
Number of subjects: 188
Study 12236025 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine stress echocardiography (n=63)
Number of subjects: 188
Study 12236025 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole perfusion scintigraphy (n=61)
Number of subjects: 188
Study 12236025 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity and extent of ischemia during dipyridamole/dobutamine stress tests
Number of subjects: 188
Study 12236025 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk category
Number of subjects: 188
Study 10416734 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g anhydrous dextrose plus 4 mg sodium saccharin
Number of subjects: 0
Study 10416734 — intervention group
Group type: COMPARATOR
Intervention: 23.7 mg saccharin alone
Number of subjects: 0
Study 7749424 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg body weight)
Number of subjects: 8
Study 7749424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2397369 — intervention group
Group type: EXPERIMENTAL
Intervention: House physicians using the questionnaire
Number of subjects: 150
Study 2397369 — intervention group
Group type: COMPARATOR
Intervention: House physicians using unstructured questions
Number of subjects: 150
Study 7437263 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous prednisolone (doses of 16, 32, 48, and 64 mg)
Number of subjects: 100
Study 7437263 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (100 mg)
Number of subjects: 100
Study 7437263 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous prednisolone (all doses)
Number of subjects: 100
Study 31076261 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 75/150 mg or 150 mg every 2 weeks
Number of subjects: 4880
Study 31076261 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 4880
Study 29899426 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg once/day (group A)
Number of subjects: 400
Study 29899426 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 200 mg twice/day (group B)
Number of subjects: 400
Study 27097864 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver Diamine Fluoride (SDF)
Number of subjects: 12
Study 27097864 — intervention group
Group type: COMPARATOR
Intervention: Control (no SDF)
Number of subjects: 12
Study 25699389 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin-containing contrast medium
Number of subjects: 280
Study 25699389 — intervention group
Group type: COMPARATOR
Intervention: Control arm (same contrast medium without Ulinastatin)
Number of subjects: 280
Study 22523090 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical thrust manipulation
Number of subjects: 80
Study 22523090 — intervention group
Group type: COMPARATOR
Intervention: Kinesio Taping
Number of subjects: 80
Study 20055751 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ibandronate (ACE 12 mg; 3 mg every 3 months and 2 mg every 2 months)
Number of subjects: 0
Study 20055751 — intervention group
Group type: COMPARATOR
Intervention: Daily oral ibandronate (ACE 5.5 mg; 2.5 mg daily)
Number of subjects: 0
Study 20055751 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ibandronate (ACE 12 mg)
Number of subjects: 0
Study 17394255 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intramuscular injection of 0.6 mg/kg dexamethasone
Number of subjects: 174
Study 16360965 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (50 mg/day for ≤75 kg or 100 mg/day for >75 kg)
Number of subjects: 29
Study 16360965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 12858465 — intervention group
Group type: EXPERIMENTAL
Intervention: Child Health Questionnaire (CHQ)
Number of subjects: 116
Study 12858465 — intervention group
Group type: COMPARATOR
Intervention: Matched controls (n = 116)
Number of subjects: 116
Study 10082498 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg)
Number of subjects: 12
Study 10082498 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (80 mg)
Number of subjects: 12
Study 10082498 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (150 mg)
Number of subjects: 12
Study 10082498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8524976 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-min cigarette spacing
Number of subjects: 10
Study 8524976 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-min cigarette spacing
Number of subjects: 10
Study 8524976 — intervention group
Group type: EXPERIMENTAL
Intervention: 120-min cigarette spacing
Number of subjects: 10
Study 8524976 — intervention group
Group type: EXPERIMENTAL
Intervention: 360-min cigarette spacing (single cigarette at end of session)
Number of subjects: 10
Study 8524976 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence for fewer than 3 hours
Number of subjects: 10
Study 2405555 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionic high-osmolar contrast medium
Number of subjects: 100
Study 2405555 — intervention group
Group type: COMPARATOR
Intervention: Non-ionic low-osmolar contrast medium
Number of subjects: 100
Study 7317308 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour therapy with Imipramine
Number of subjects: 126
Study 7317308 — intervention group
Group type: COMPARATOR
Intervention: Behaviour therapy with placebo
Number of subjects: 126
Study 7317308 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive therapy with Imipramine
Number of subjects: 126
Study 7317308 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 126
Study 31369961 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigated patellar resurfacing
Number of subjects: 20
Study 29781483 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil 0.31 g d‐1
Number of subjects: 201
Study 29781483 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil 0.62 g d‐1
Number of subjects: 201
Study 29781483 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil 1.24 g d‐1
Number of subjects: 201
Study 29781483 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 201
Study 26707220 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine (PCV/PPV)
Number of subjects: 100
Study 26707220 — intervention group
Group type: COMPARATOR
Intervention: 23-valent pneumococcal polysaccharide vaccine (PPV) only
Number of subjects: 100
Study 26707220 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV/PPV
Number of subjects: 100
Study 24865680 — intervention group
Group type: EXPERIMENTAL
Intervention: Sawyer PointONE filters
Number of subjects: 952
Study 24865680 — intervention group
Group type: EXPERIMENTAL
Intervention: Sawyer PointONE filters and WASH BCC
Number of subjects: 952
Study 24865680 — intervention group
Group type: COMPARATOR
Intervention: WASH BCC
Number of subjects: 952
Study 21839620 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 0
Study 21839620 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR
Number of subjects: 0
Study 18783876 — intervention group
Group type: EXPERIMENTAL
Intervention: UNS RP plus sural nerve grafting (SNG)
Number of subjects: 107
Study 18783876 — intervention group
Group type: COMPARATOR
Intervention: UNS RP alone (Control)
Number of subjects: 107
Study 18783876 — intervention group
Group type: EXPERIMENTAL
Intervention: UNS RP plus SNG
Number of subjects: 107
Study 16782102 — intervention group
Group type: EXPERIMENTAL
Intervention: SP6 acupressure
Number of subjects: 58
Study 16782102 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (light touch on SP6 acupoint)
Number of subjects: 58
Study 15072399 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral approach to sciatic nerve block with 1% mepivacaine
Number of subjects: 60
Study 15072399 — intervention group
Group type: COMPARATOR
Intervention: Posterior approach to sciatic nerve block with 1% mepivacaine
Number of subjects: 60
Study 11668312 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (150 mg daily)
Number of subjects: 32
Study 11668312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 11668312 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 32
Study 9852980 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir
Number of subjects: 0
Study 9852980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7780294 — intervention group
Group type: EXPERIMENTAL
Intervention: 40‐mg intravenous cocaine injections
Number of subjects: 29
Study 7780294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 3182119 — intervention group
Group type: EXPERIMENTAL
Intervention: Tulobuterol (2 mg, twice daily)
Number of subjects: 0
Study 3182119 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (2.5 mg, thrice daily)
Number of subjects: 0
Study 3182119 — intervention group
Group type: COMPARATOR
Intervention: Tulobuterol
Number of subjects: 0
Study 3182119 — intervention group
Group type: COMPARATOR
Intervention: Fenoterol
Number of subjects: 0
Study 3182119 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 0
Study 31010703 — intervention group
Group type: EXPERIMENTAL
Intervention: Leap Motion Controller-based training (LMCBT)
Number of subjects: 103
Study 31010703 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 103
Study 29676673 — intervention group
Group type: EXPERIMENTAL
Intervention: Depo-Medrol (DEPO)
Number of subjects: 104
Study 29676673 — intervention group
Group type: COMPARATOR
Intervention: No Depo-Medrol (NODEPO)
Number of subjects: 104
Study 27324086 — intervention group
Group type: EXPERIMENTAL
Intervention: Free gaze condition
Number of subjects: 0
Study 27324086 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed gaze condition
Number of subjects: 0
Study 24820831 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (10 billion cfu/day for five days)
Number of subjects: 2000
Study 24820831 — intervention group
Group type: COMPARATOR
Intervention: Control (no probiotic medication)
Number of subjects: 2000
Study 22285946 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg CLMWF
Number of subjects: 12
Study 22285946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 20583960 — intervention group
Group type: COMPARATOR
Intervention: Monopolar transurethral resection of the prostate (TURP)
Number of subjects: 518
Study 20583960 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar transurethral resection in saline (TURIS)
Number of subjects: 518
Study 18669464 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib (50 mg orally once daily for 4 weeks, followed by 2 weeks off)
Number of subjects: 750
Study 18669464 — intervention group
Group type: COMPARATOR
Intervention: Interferon alfa (9 million units subcutaneous injections, three times weekly)
Number of subjects: 750
Study 18669464 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 750
Study 15904908 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc gluconate supplementation with IFN-alpha-2a/ribavirin
Number of subjects: 40
Study 15904908 — intervention group
Group type: COMPARATOR
Intervention: IFN-alpha-2a/ribavirin without zinc supplementation
Number of subjects: 40
Study 12736474 — intervention group
Group type: EXPERIMENTAL
Intervention: Torasemide at 4-8 mg/day
Number of subjects: 50
Study 12736474 — intervention group
Group type: COMPARATOR
Intervention: Furosemide at 20-40 mg/day
Number of subjects: 50
Study 10230947 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium chloride (CaCl2) 10 mg/kg administered simultaneously with propofol
Number of subjects: 58
Study 10230947 — intervention group
Group type: COMPARATOR
Intervention: Saline administered simultaneously with propofol
Number of subjects: 58
Study 8653836 — intervention group
Group type: EXPERIMENTAL
Intervention: CNP at 500 pmol/min
Number of subjects: 16
Study 8653836 — intervention group
Group type: COMPARATOR
Intervention: Hydralazine at 10 μg/min (control)
Number of subjects: 16
Study 7904993 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxatidine 75 mg twice daily
Number of subjects: 47
Study 7904993 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 200 mg 3 times a day and 400 mg at bed time
Number of subjects: 47
Study 3327445 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous indomethacin 0.35 mg/kg followed by an infusion of 0.07 mg/kg/h for 24 h
Number of subjects: 100
Study 3327445 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous indomethacin
Number of subjects: 100
Study 3327445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 31948661 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid (O-3FA) 4 g/day
Number of subjects: 325
Study 31948661 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 325
Study 29580591 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy (AT)
Number of subjects: 254
Study 29580591 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 254
Study 28479218 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI screening and reporting
Number of subjects: 79
Study 28479218 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI screening only
Number of subjects: 79
Study 28479218 — intervention group
Group type: COMPARATOR
Intervention: No BMI screening or reporting
Number of subjects: 79
Study 28479218 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI reporting (BMI results alone or both BMI and fitness test results)
Number of subjects: 79
Study 28479218 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI reports
Number of subjects: 79
Study 26052677 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTA
Number of subjects: 400